CRMD CorMedix Inc.
USHealthcareAs of 2026-07-09 16:00
Why CRMD matters now
CorMedix Inc. (CRMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.67 with -1.81% on the session and $680.2M in market capitalization; recent performance reads 1-month +10.87% and YTD -25.45%.
The latest financial table shown here is Q1 2026, with revenue of $127.4M, net income of $38.6M, and EPS of $0.42. Investors can compare that operating picture with valuation signals such as P/E 3.51 and FCF yield 28.9%.
The latest indexable market news headline is "Is CRMD Stock a Buy Now After Strong Growth and New Risks?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $13.50; recent insider activity includes Todisco Joseph filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
3.51
PEG
0.00
P/B
1.58
P/S
1.70
EV/EBITDA
3.04
DCF Value
$2.50
FCF Yield
28.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.8%
Operating Margin
48.4%
Net Margin
45.2%
ROE
50.4%
ROA
22.2%
ROIC
27.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $127.4M | $38.6M | $0.42 |
| Q4 2025 | $128.6M | $14.0M | $0.15 |
| FY 2025 | $311.7M | $163.1M | $2.04 |
| Q3 2025 | $104.3M | $108.6M | $1.26 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$14.00
Target (Median)
$13.50
Target Range
$13.00 - $16.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.47
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.